A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : 2-CdA / 2-chlorodeoxyadenosine

[Related PubMed/MEDLINE]
Total Number of Papers: 262
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   2-CdA  (>> Co-occurring Abbreviation)
Long Form:   2-chlorodeoxyadenosine
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Isolation and characterization of a CD34+ sub-clone in B-cell lymphoma. aCGH, B-NHL, CR, FCM, NHL, PCR, PDS
2019 Successful treatment with 2-chlorodeoxyadenosine of refractory pediatric Langerhans cell histiocytosis with initial involvement of the gastrointestinal tract. GI, LCH, PLE
2015 Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004. AML, HR
2014 Modulation of deoxycytidine kinase (dCK) and glycogen synthase kinase (GSK-3beta) by anti-CD20 (rituximab) and 2-chlorodeoxyadenosine (2-CdA) in human lymphoid malignancies. dCK, GSK-3beta, HSD, p38 MAPK
2013 Langerhans cell sarcoma of the nasopharynx: a rare case. ---
2013 Older and new purine nucleoside analogs for patients with acute leukemias. ALL, AML, PNAs
2013 Primary therapy of Waldenstrom macroglobulinemia with nucleoside analogue-based therapy. DOR, NAs, ORR, OS, PFS, WM
2013 Spontaneous remission of 2-chlorodeoxyadenosine (2-CdA)-related secondary myelodysplastic syndrome in a patient with refractory Langerhans cell histiocytosis. LCH, MDS
2012 Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice. MS
10  2012 Optimal therapy for adults with Langerhans cell histiocytosis bone lesions. LCH
11  2012 Phase II study of 2-chlorodeoxyadenosine plus idarubicin for children with acute myeloid leukaemia in first relapse: a paediatric oncology group study. AML, CR, EFS, IDA, OS
12  2012 Severe persistent bone marrow failure following therapy with 2-chlorodeoxyadenosine for relapsing juvenile xanthogranuloma of the brain. JXG
13  2011 Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. HCL, MM, p-STAT3, STAT3
14  2010 2-Chlorodeoxyadenosine treatment for cutaneous T-cell lymphoma. CTCL
15  2010 Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenstrom's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. 5'-NT, hCNT1, SLL, WM
16  2010 Juvenile xanthogranuloma with hematological dysfunction treated with 2CDA-AraC. ---
17  2010 Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. LCH, MFB, MS, RO
18  2010 Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. CR, hCNT1, s.c, WM, Zap-70
19  2009 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society. LCH
20  2009 Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. HU, IFN-alpha, IM, SM, SM-AHNMD
21  2009 Extranodal multifocal Rosai-Dorfman disease: response to 2-chlorodeoxyadenosine treatment. 18FDG, NHL, RDD
22  2009 Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. LCH
23  2008 Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor. ChIP, DSRCT, ENT4
24  2008 Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. CNS, DI, LCH
25  2008 Complete remission of nodular pulmonary Langerhans cell histiocytosis lesions induced by 2-chlorodeoxyadenosine in a non-smoker. LCH
26  2006 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up. CR
27  2006 Enforced expression of cytosolic 5'-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection. 5-FU, cN-I
28  2006 Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. NHL
29  2006 Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. CR, DCF, HCL, IFN-alpha, PR
30  2006 Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine. CR, LCH
31  2005 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. CR, HES
32  2005 Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide. HCL, TRAP
33  2005 Hairy cell leukemia: clinical presentation and long term follow up after treatment with 2-chlorodeoxyadenosine (2-CdA). ---
34  2005 Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. MMM
35  2005 Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. LCH, WHO
36  2005 Phase II clinical study of cladribine in the treatment of hairy cell leukemia. CR, HCL
37  2005 Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. CR, HCL, OS, PFS, PR
38  2004 Acquired factor VIII inhibitors in non-haemophilic patients: clinical experience of 15 cases. CR
39  2004 An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. CR, dCF, HCL, mo, pts
40  2004 Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. MDS
41  2004 In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. ALL, HOO, L-ASP, LRP, PRED
42  2004 Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. CR, HCL, PR
43  2004 Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. AL, MDS
44  2004 Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. CLL
45  2004 Rituximab as treatment for minimal residual disease in hairy cell leukaemia. CR, HCL, MRD, PCR, PR
46  2004 The influence of 2-chlorodeoxyadenosine (2-CdA) on the adenine energy charge and glutathione content of human erythrocytes. AEC
47  2004 Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. IFN-alpha, SMCD
48  2003 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. CI, CY, PR, PRED, RIT, SC, WM
49  2003 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. LCH
50  2003 Cutaneous reactions in hairy cell leukaemia treated with 2-chlorodeoxyadenosine and allopurinol. ---
51  2003 Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia. BUs
52  2003 Hairy cell leukaemia with advanced treatment - a case report. ANC, HC, HCL, TRAP
53  2003 Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. AML
54  2003 Splenectomy and treatments of historical interest. HCL
55  2003 Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. LCH
56  2003 The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro. CML, CsA, MNCs, PNAs
57  2003 Treatment of cutaneous T-cell lymphomas with purine analogues (fludarabine and 2-chlorodeoxyadenosine). CTCL, CY
58  2002 Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues. CLL, HCL, SCC
59  2002 Complete remission of chronic plaque psoriasis and gastric marginal zone B-cell lymphoma of MALT type after treatment with 2-chlorodeoxyadenosine. MALT
60  2002 Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content. ALL, ara-C, NT
61  2002 Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia. AI, B-CLL, DOX, IDA, MIT
62  2002 Exposure-disease continuum for 2-chloro-2'-deoxyadenosine (2-CdA), a prototype teratogen: induction of lumbar hernia in the rat and species comparison for the teratogenic responses. GD
63  2002 Fludarabine therapy in Waldenstrom's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine. WM
64  2002 Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. ---
65  2002 Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. LCH
66  2002 Treatment of late-stage Sezary syndrome with 2-Chlorodeoxyadenosine. ---
67  2001 Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. AML, BMT, CR, EFS, FAB, MDS
68  2001 Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. CR, EFS
69  2001 Langerhans cell histiocytosis: central nervous system involvement treated successfully with 2-chlorodeoxyadenosine. CNS
70  2001 Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line. bryo 1, CLL, IAP
71  2001 Unexpectedly high incidence of hypoplastic/aplastic foci in bone marrow biopsies of hairy cell leukemia patients in remission following 2-chlorodeoxyadenosine therapy. ---
72  2001 [Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis. Study of 9 patients]. CR, DFS, LCH, OS, PR
73  2000 2-chlorodeoxyadenosine (2-CdA) does not change the expression of Fas antigen on chronic lymphocytic leukaemia cells. ---
74  2000 2-Chlorodeoxyadenosine treatment of Waldenstrom's macroglobulinemia--the analysis of own experience and the review of literature. MW
75  2000 Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells. ---
76  2000 Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. AML, CR
77  2000 Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388. DEX, MST
78  2000 Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. sIL-2R
79  2000 Enhancement of retention and cytotoxicity of 2-chlorodeoxyadenosine in cultured human leukemic lymphoblasts by nitrobenzylthioinosine, an inhibitor of equilibrative nucleoside transport. DPM
80  2000 Hairy cell leukemia in Hong Kong Chinese: a 12-year retrospective survey. B-LPD, HCL
81  2000 Induction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone. ---
82  2000 Influence of gemcitabine (2',2'-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro. CFU-GM, CML
83  2000 Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. CR, DCF, HCL, PR
84  2000 Mycobacterium-avium-intracellulare complex infection following 2-chlorodeoxyadenosine therapy for hairy cell leukaemia. HCL, MAC
85  2000 Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. APAF-1
86  2000 Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995. AML, ECOG
87  2000 Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report. Bryo-1, CLL
88  2000 Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution. ---
89  2000 The influence of amifostine used alone or in combination with 2-chlorodeoxyadenosine on normal and chronic myelogenous leukemia granulocyte-macrophage progenitor cells in vitro. CML, IDMEM, MNCs
90  2000 [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine]. MRD, sIL-2R
91  1999 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. B-CLL, CR, PR
92  1999 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. HCL, HCLv, IFN-alpha, PFS
93  1999 2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. B-CLL, CR, PR
94  1999 Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388. MST
95  1999 Attempted reconstruction of the immune system using low doses of interleukin 2 in chronic lymphocytic leukemia patients treated with 2-chlorodeoxyadenosine: results of a pilot study. ---
96  1999 Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenstrom's macroglobulinemia. CR, MW, PR
97  1999 Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. BMB, HCL
98  1999 Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a B-CLL cell line. Bryo 1, IR
99  1999 Long-lasting decrease of CD4+/CD45RA+ T cells in HCL patients after 2-chlorodeoxyadenosine (2-CdA) treatment. HCL
100  1999 Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine. dCF, HCL